Manuscripts
Showing 1591 manuscripts.
Antiretroviral choice and severe disease predict poorer neuropsychological outcomes in HIV+ children from Africa
Citation
Lee Fairlie, Miriam Chernoff, Mark F. Cotton, Mutsa Bwakura-Dangarembizi, Avy Violari, Itziar Familiar-Lopez, Linda Barlow-Mosha, Portia Kamthunzi, Katie Mccarthy, Patrick Jean-Philippe, Barbara Laughton, Paul E Palumbo, Michael J Boivin. Antiretroviral choice and severe disease predict poorer neuropsychological outcomes in HIV+ children from Africa. Frontiers in Pediatrics. 2022 Aug 03; 10:899002. PMID: 35989995; PMCID: PMC9382189.Year
2022
Journal
Frontiers in Pediatrics
Study
P1104s
Growth deficits in antiretroviral and HIV-exposed uninfected versus unexposed children in Malawi and Uganda persist through 60 months of age.
Citation
Fowler MG, Aizire J, Sikorskii A, Atuhaire P, Ogwang LW, Mutebe A, Katumbi C, Maliwichi L, Familiar I, Taha T, Boivin MJ, PROMISE-NEURODEV study team. Growth deficits in antiretroviral and HIV-exposed uninfected versus unexposed children in Malawi and Uganda persist through 60 months of age. AIDS. 2022 Mar 15; 36(4):573-582. PMID: 34750297; PMCID: PMC9097628.Year
2022
Journal
AIDS
High Prevalence of Tuberculosis Infection and Disease in Child Household Contacts of Adults With Rifampin-resistant Tuberculosis
Citation
Kim S, Wu X, Hughes MD, Upton C, Narunsky K, Mendoza-Ticona A, Khajenoori S, Gonzales P, Badal-Faesen S, Shenje J, Omoz-Oarhe A, Rouzier V, Garcia-Prats AJ, Demers AM, Naini L, Smith E, Churchyard G, Swindells S, Shah NS, Gupta A, Hesseling AC, ACTG A5300/IMPAACT 2003/PHOENix Feasibility Study Team. High Prevalence of Tuberculosis Infection and Disease in Child Household Contacts of Adults With Rifampin-resistant Tuberculosis. Pediatric Infectious Disease Journal. 2022 May 01; 41(5):194-202. PMID: 35239624; PMCID: PMC9007870.Year
2022
Journal
Pediatric Infectious Disease Journal
Study
IMPAACT 2003/ACTG 5300
Host transcriptomic signatures of tuberculosis can predict immune reconstitution inflammatory syndrome in HIV patients.
Citation
Mbandi SK, Painter H, Penn-Nicholson A, Toefy A, Erasmus M, Hanekom WA, Scriba TJ, Lai RPJ, Marais S, Fletcher HA, Meintjes G, Wilkinson RJ, Cotton MF, Pahwa S, Cameron MJ, Nemes E. Host transcriptomic signatures of tuberculosis can predict immune reconstitution inflammatory syndrome in HIV patients. European Journal of Immunology. 2022 Jul 01; 52(7):1112-1119. PMID: 35398886; PMCID: PMC9276552.Year
2022
Journal
European Journal of Immunology
Current strategies to induce selective killing of HIV-1-infected cells.
Citation
Campbell GR, Spector SA. Current strategies to induce selective killing of HIV-1-infected cells. Journal of Leukocyte Biology. 2022 Jun 16; PMID: 35707952.Year
2022
Journal
Journal of Leukocyte Biology
Pharmacokinetics, safety, tolerability and antiviral activity of dolutegravir dispersible tablets in infants and children with HIV-1: results of the IMPAACT P1093 study, a phase I/II open-label trial
Citation
Theodore D. Ruel, Edward P. Acosta, Jessica P. Liu, Kathryn P. Gray, Kathleen George, Nicole MontaƱez, Stephanie Popson, Ann M. Buchanan, Mattie Bartlett, Dale Dayton, Patricia Anthony, Cynthia Brothers, Cynthia Vavro, Rajendra Singh, Lucy Koech, Tichaona Vhembo, Rohan Hazra, Ellen Townley, Andrew Wiznia, IMPAACT P1093 Team. Pharmacokinetics, safety, tolerability and antiviral activity of dolutegravir dispersible tablets in infants and children with HIV-1: results of the IMPAACT P1093 study, a phase I/II open-label trial. Lancet HIV. 2022 May 01; PMID: 35489377; PMCID: PMC9313528.Year
2022
Journal
Lancet HIV
Study
P1093
Leveraging physiologically based pharmacokinetic modeling to optimize dosing for lopinavir/ritonavir with rifampin in pediatric patients
Citation
Sara N Salerno, Edmund V Capparelli, Helen McIlleron, Jacqueline G Gerhart, Julie B Dumond, Angela D M Kashuba, Paolo Denti, Daniel Gonzalez. Leveraging physiologically based pharmacokinetic modeling to optimize dosing for lopinavir/ritonavir with rifampin in pediatric patients. Journal of the American College of Clinical Pharmacy. 2022 May 24; PMID: 35607886.Year
2022
Journal
Journal of the American College of Clinical Pharmacy
Interactions between etonogestrel-releasing contraceptive implant and 3 antiretroviral regimens
Citation
Regis Kreitchmann, Alice Stek, Brookie M Best, Edmund Capparelli, Jiajia Wang, David Shapiro, Nahida Chakhtoura, Mark Mirochnick, Ahizechukwu C Eke, IMPAACT P1026s protocol team. Interactions between etonogestrel-releasing contraceptive implant and 3 antiretroviral regimens. Contraception. 2022 Jan 01; 105:67-74. PMID: 34407424; PMCID: PMC8678338.Year
2022
Journal
Contraception
Study
P1026S
Validation and application of a quantitative liquid chromatography tandem mass spectrometry assay for the analysis of rifapentine and 25-O-desacetyl rifapentine in human milk
Citation
Buyisile Mkhize, Tracy Kellermann, Jennifer Norman, Sandra Castel, Anton Joubert, Kelly E. Dooley, Jyoti S. Mathad, Lubbe Wiesner. Validation and application of a quantitative liquid chromatography tandem mass spectrometry assay for the analysis of rifapentine and 25-O-desacetyl rifapentine in human milk. Journal of Pharmaceutical and Biomedical Analysis. 2022 Jun 05; 215(114774). PMID: 35462285; PMCID: PMC9871952.Year
2022
Journal
Journal of Pharmaceutical and Biomedical Analysis
Study
IMPAACT 2001
Brief Report: Impact of Antiretroviral Regimen on Pregnancy and Infant Outcomes in Women With HIV/ HBV Coinfection
Citation
Flavia Matovu Kiweewa, Camlin Tierney, Kevin Butler, Marion G. Peters, Tichaona Vhembo, Dhayendre Moodley, Vani Govender, Neaka Mohtashemi, Hannah Ship, Philippa Musoke, Dingase Dula, Kathy George, Nahida Chakhtoura, Mary G. Fowler, Judith S. Currier, Debika Bhattacharya. Brief Report: Impact of Antiretroviral Regimen on Pregnancy and Infant Outcomes in Women With HIV/ HBV Coinfection. Journal of AIDS. 2022 Sep 01; 91(1):79-84. PMID: 35621877; PMCID: 9377493.Year
2022
Journal
Journal of AIDS
Study
1077BF, 1077FF